Welcome!

News Feed Item

European Researchers Invited to Submit Study Proposals for Bristol-Myers Squibb's Partnering for Cure™ Virology Research Programme

PARIS, April 8, 2014 /PRNewswire/ --

Partnering for Cure is Bristol-Myers Squibb's flagship, Pan-European scientific initiative supporting breakthrough research and facilitating greater collaboration and knowledge-sharing with the virology community 

In advance of this year's International Liver CongressTM 2014 in London, England, Bristol-Myers Squibb invites European researchers to submit innovative research ideas that aim to cure chronic virological diseases. As part of Bristol-Myers Squibb's ongoing commitment in virology, these projects provide an opportunity for researchers, particularly junior faculty and young investigators, to accelerate novel solutions that could lead to cures in HIV, hepatitis B (HBV) and hepatitis C (HCV).

This latest round of research applications will be accepted from 1 May to 15 July 2014 and aspiring scientists are encouraged to submit their ideas at http://www.bms.com/israpplications. Priority will be given to research proposals in the area of translational science with a clear relevance for the clinical development of a cure in viral hepatitis or HIV infection.

Partnering for Cure is led by the Partnering for CureFaculty, an expert panel of clinical and research experts from across Europe and focuses on three pillars - education, scientific exchange and scientific research. The Faculty will award up to four recipients in a blinded evaluation after applications close. The four research applicants will share between them just over €300,000 in support from Bristol-Myers Squibb.

"This year, we were proud to announce our first class of Partnering for Cureresearch programme recipients in January," said Professor Jürgen Rockstroh, Partnering for Cure Faculty Chair. "Now we're looking for even more proposals to expand our clinical network and continuing the fight against chronic viral diseases through the 2014 Partnering for Cure research programme."  

Matthieu Perreau, Centre Hospitalier Universitaire Vaudois (CHUV) Service Immunologie et Allergie, Switzerland, was one of the four Partnering for Cure research programme recipients last year, awarded for his research, Identification of the memory CD4 T-cell population(s) harbouring replication competent HIV-1 within lymphoid tissues.

"This grant has provided me with the opportunity to pursue my passion and make an impact in the virology community," remarks Perreau. "It is an honour to be part of this exciting initiative, and I look forward to working with my research colleagues to find a cure."

"Bristol-Myers Squibb has a longstanding vision of continuing to transform the treatment of viral diseases and fulfilling serious unmet medical needs of patients," said George Hanna, MD, vice president, HIV Development, Bristol-Myers Squibb. "We look forward to this year's applications and supporting the upcoming generation of researchers and scientists who are dedicated to improving treatments and delivering true advances in patient care."

The projects that will receive support from Bristol-Myers Squibb will be announced on World AIDS Day - 1 December 2014.

About Partnering for Cure 

Partnering for Cure is a European medical education programme developed as part of Bristol-Myers Squibb's ongoing commitment to virology research, education and transforming clinical outcomes for patients with chronic viral diseases. The programme focuses on recent and ongoing cure research in HIV, HBV and HCV.

The objectives of the programme are to:

  • Provide medical education to physicians interested in virology cure research
  • Provide support to researchers active in virology cure research
  • Provide a forum for physicians and researchers to discuss advances in virology cure

The Partnering for Cure initiative reinforces Bristol-Myers Squibb's commitment in virology, which is rooted in the company's legacy in virology and ongoing research in HIV and viral hepatitis. Chronic viral infections make a substantial contribution to the burden of chronic diseases and premature mortality worldwide. In December 2012, the Global Burden of Disease Study reported 1,465,000 deaths caused by HIV/AIDS and 1,445,000 deaths caused by viral hepatitis in 2010.[i] Infections with hepatitis B and C viruses also cause an estimated 57 percent of cases of liver cirrhosis and 78 percent of cases of primary liver cancer annually.[ii] Whilst important advances have been made over the last decade significant unmet needs and the opportunity for cure remains, particularly in HIV.

Bristol-Myers Squibb's Commitment to Virology 

For over 20 years, Bristol-Myers Squibb has worked collaboratively with the virology community to help meet the needs of patients living with HIV, HBV and HCV - by providing and developing medicines such as Zerit®, Videx®, Sustiva®, Atripla[®*], Reyataz®, Baraclude®, supporting clinical research on new innovative compounds, supporting disease education efforts, and improving access to medicines in the developing world.

Bristol-Myers Squibb supports a number of scientific and educational programs within the virology community around the world that encompass disease education, disease awareness and sharing of best practices. In addition to Partnering for Cure these include SHE® (Strong, HIV positive, Empowered Women/Strong, HIV positive Women Educational Programme), a comprehensive and innovative programme for women living with HIV and their healthcare providers, PATH B® (Patients and professionals acting together for hepatitis B), a joint initiative between hepatitis patient groups and hepatologists to provide comprehensive information and support for patients with chronic hepatitis B.

Additionally, Bristol-Myers Squibb Foundation's philanthropic and educational programmes, such as Secure the Future® and Delivering Hope® aim to support people living with HIV in Africa and with viral hepatitis in Asia, through numerous private-public partnerships and community based projects.

VIRUK14NP01991-01

Prepared April 2014

* Atripla® is a trademark of Bristol-Myers Squibb Co. and Gilead Sciences, Inc.

i. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010, The Lancet, Volume 380, No9859, Dec 15, 2012 pp2095-2128

ii. WHO and WHA, Global Policy Report on the Prevention and Control of Viral Hepatitis, 2013, http://global-report.worldhepatitisalliance.org/en/home.html


More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Manufacturers are embracing the Industrial Internet the same way consumers are leveraging Fitbits – to improve overall health and wellness. Both can provide consistent measurement, visibility, and suggest performance improvements customized to help reach goals. Fitbit users can view real-time data and make adjustments to increase their activity. In his session at @ThingsExpo, Mark Bernardo Professional Services Leader, Americas, at GE Digital, discussed how leveraging the Industrial Internet and...
SYS-CON Events announced today that delaPlex will exhibit at SYS-CON's @CloudExpo, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. delaPlex pioneered Software Development as a Service (SDaaS), which provides scalable resources to build, test, and deploy software. It’s a fast and more reliable way to develop a new product or expand your in-house team.
Web Real-Time Communication APIs have quickly revolutionized what browsers are capable of. In addition to video and audio streams, we can now bi-directionally send arbitrary data over WebRTC's PeerConnection Data Channels. With the advent of Progressive Web Apps and new hardware APIs such as WebBluetooh and WebUSB, we can finally enable users to stitch together the Internet of Things directly from their browsers while communicating privately and securely in a decentralized way.
"Matrix is an ambitious open standard and implementation that's set up to break down the fragmentation problems that exist in IP messaging and VoIP communication," explained John Woolf, Technical Evangelist at Matrix, in this SYS-CON.tv interview at @ThingsExpo, held Nov 4–6, 2014, at the Santa Clara Convention Center in Santa Clara, CA.
Information technology (IT) advances are transforming the way we innovate in business, thereby disrupting the old guard and their predictable status-quo. It’s creating global market turbulence. Industries are converging, and new opportunities and threats are emerging, like never before. So, how are savvy chief information officers (CIOs) leading this transition? Back in 2015, the IBM Institute for Business Value conducted a market study that included the findings from over 1,800 CIO interviews ...
Web Real-Time Communication APIs have quickly revolutionized what browsers are capable of. In addition to video and audio streams, we can now bi-directionally send arbitrary data over WebRTC's PeerConnection Data Channels. With the advent of Progressive Web Apps and new hardware APIs such as WebBluetooh and WebUSB, we can finally enable users to stitch together the Internet of Things directly from their browsers while communicating privately and securely in a decentralized way.
"We host and fully manage cloud data services, whether we store, the data, move the data, or run analytics on the data," stated Kamal Shannak, Senior Development Manager, Cloud Data Services, IBM, in this SYS-CON.tv interview at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.
While DevOps most critically and famously fosters collaboration, communication, and integration through cultural change, culture is more of an output than an input. In order to actively drive cultural evolution, organizations must make substantial organizational and process changes, and adopt new technologies, to encourage a DevOps culture. Moderated by Andi Mann, panelists discussed how to balance these three pillars of DevOps, where to focus attention (and resources), where organizations might...
Zerto exhibited at SYS-CON's 18th International Cloud Expo®, which took place at the Javits Center in New York City, NY, in June 2016. Zerto is committed to keeping enterprise and cloud IT running 24/7 by providing innovative, simple, reliable and scalable business continuity software solutions. Through the Zerto Cloud Continuity Platform™, organizations can seamlessly move and protect virtualized workloads between public, private and hybrid clouds. The company’s flagship product, Zerto Virtual...
Some people worry that OpenStack is more flash then substance; however, for many customers this could not be farther from the truth. No other technology equalizes the playing field between vendors while giving your internal teams better access than ever to infrastructure when they need it. In his session at 20th Cloud Expo, Chris Brown, a Solutions Marketing Manager at Nutanix, will talk through some real-world OpenStack deployments and look into the ways this can benefit customers of all sizes....
Extreme Computing is the ability to leverage highly performant infrastructure and software to accelerate Big Data, machine learning, HPC, and Enterprise applications. High IOPS Storage, low-latency networks, in-memory databases, GPUs and other parallel accelerators are being used to achieve faster results and help businesses make better decisions. In his session at 18th Cloud Expo, Michael O'Neill, Strategic Business Development at NVIDIA, focused on some of the unique ways extreme computing is...
The explosion of new web/cloud/IoT-based applications and the data they generate are transforming our world right before our eyes. In this rush to adopt these new technologies, organizations are often ignoring fundamental questions concerning who owns the data and failing to ask for permission to conduct invasive surveillance of their customers. Organizations that are not transparent about how their systems gather data telemetry without offering shared data ownership risk product rejection, regu...
Due of the rise of Hadoop, many enterprises are now deploying their first small clusters of 10 to 20 servers. At this small scale, the complexity of operating the cluster looks and feels like general data center servers. It is not until the clusters scale, as they inevitably do, when the pain caused by the exponential complexity becomes apparent. We've seen this problem occur time and time again. In his session at Big Data Expo, Greg Bruno, Vice President of Engineering and co-founder of StackIQ...
The security needs of IoT environments require a strong, proven approach to maintain security, trust and privacy in their ecosystem. Assurance and protection of device identity, secure data encryption and authentication are the key security challenges organizations are trying to address when integrating IoT devices. This holds true for IoT applications in a wide range of industries, for example, healthcare, consumer devices, and manufacturing. In his session at @ThingsExpo, Lancen LaChance, vic...
"Plutora provides release and testing environment capabilities to the enterprise," explained Dalibor Siroky, Director and Co-founder of Plutora, in this SYS-CON.tv interview at @DevOpsSummit, held June 9-11, 2015, at the Javits Center in New York City.